BTK and Miyoshi myopathy: In a mouse xenograft human MM model, a combination of the BTK inhibitor CC-292 (spebrutinib, Celgene Corporation) with the proteasome inhibitor carfilzomib increased vertebral trabecular bone mass compared to carfilzomib alone and reduced tumor burden [10].